ABBVAbbVieNot started yet
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
Amyloid Light Chain (AL) Amyloidosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 370 (planned)
- Started
- Nov 29, 2026
- Main results expected
- Dec 2034
- Fully finished
- Dec 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events
Measured over: Up to Approximately 96 Months
Randomized Portion: Complete Hematologic Response (HemeCR) Rate
Measured over: Up to Approximately 60 Months
Randomized Portion: Major Organ Deterioration Progression-Free Survival (MOD-PFS)
Measured over: Up to Approximately 60 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07793422 · record last updated 2026-08-28 · checked 2026-11-09 15:47 UTC